Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features

PHASE1UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
CarcinoidNeuroendocrine
Interventions
DRUG

Seneca Valley Virus (biological agent)

Dose escalation (starting at 1 × 10\^7 vp/kg), IV (in the vein) over 1 hour in a single administration

Trial Locations (10)

12208

New York Oncology Hematology P.C., Albany

21231

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

23502

Virginia Oncology Associates, Norfolk

29605

Cancer Centers of the Carolinas, Greenville

34761

Cancer Centers of Florida, Ocoee

45409

Dayton Oncology & Hematology, P.A ., Kettering

46219

Central Indiana Cancer Centers, Indianapolis

75201

Mary Crowley Research Center, Dallas

75702

Tyler Cancer Center, Tyler

98684

Northwest Cancer Specialists - Vancouver Cancer Center, Vancouver

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Neotropix

INDUSTRY